Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06695182

the Real-world Data of Risk Factor and Its Prognosis in PREmature Coronary ARtery DIseAse Study

The goal of this observational study is to explore the relationship between biological aging and long-term prognosis of patients with metabolic cardiovascular disease in premature coronary artery disease. The main question[s] it aims to answer [is/are]:

1. Do patients with premature coronary heart disease have accelerated biological aging? 2. What is the prognosis of accelerated biological aging in patients with premature coronary heart disease?

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female inpatients over 18 years old in the Department of Cardiovascular Medicine;
  • Patients with one of the following metabolic cardiovascular diseases [17]: including diabetes, hypertension, coronary heart disease, heart failure, cerebral infarction, dyslipidemia, obesity and hyperuricemia;
  • Those who have corresponding inspection data so as to be able to calculate the biological age;
  • Obtaining oral informed consent or signing an informed consent form;

Exclusion criteria

·NA

Treatment and study plan

Physical activity

Behavioral

Primary outcomes

  1. International physical activity questionnaire

    Time frame: Baseline.

    The duration and form of exercise (low, moderate and high intensity) was reported in the form of recall, with higher scores representing more exercise.

  2. Accelerometer

    Time frame: Up to 8 weeks.

    Record participants' daily exercise, more objective than questionnaires.

  3. Cardiopulmonary test

    Time frame: Up to 8 weeks.

    Representation of extreme and sub-extreme motion.

  4. Glucose

    Time frame: Up to 8 weeks.

    Measurement of fasting blood glucose levels to evaluate changes in glucose metabolism and glycemic control. Fasting blood samples are collected in the morning following an 8- to 12-hour fast. Blood glucose concentration is measured in milligrams per deciliter (mg/dL) using a standardized laboratory analyzer to ensure accuracy and consistency.

  5. Hemoglobin A1c (HbA1c)

    Time frame: Up to 8 weeks.

    Measurement of Hemoglobin A1c (HbA1c) levels to evaluate long-term glycemic control over the past 2-3 months. HbA1c is measured as a percentage using a high-performance liquid chromatography (HPLC) method, providing an indication of average blood glucose levels.

  6. Serum creatinine

    Time frame: Up to 8 weeks.

    Measurement of serum creatinine levels to assess renal function and monitor potential changes over time. Serum creatinine is measured in milligrams per deciliter (mg/dL) using an enzymatic assay in a certified laboratory. This measurement serves as a key indicator of kidney function and is used to calculate the estimated glomerular filtration rate (eGFR) as an additional marker of renal health.

  7. Lipid

    Time frame: Up to 8 weeks.

    Measurement of lipid profile, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides, to evaluate cardiovascular risk and lipid metabolism. Fasting blood samples are collected after an 8- to 12-hour fast and analyzed in a certified laboratory using enzymatic colorimetric assays. Results are expressed in milligrams per deciliter (mg/dL).

  8. Serum uric acid

    Time frame: Up to 8 weeks.

    Measurement of serum uric acid levels to assess purine metabolism and monitor for potential hyperuricemia. Serum uric acid is measured in milligrams per deciliter (mg/dL) using an enzymatic colorimetric method in a certified laboratory. This measure provides insight into kidney function and potential risk of gout.

  9. Blood urea nitrogen

    Time frame: Up to 8 weeks.

    Measurement of blood urea nitrogen (BUN) levels to evaluate kidney function and protein metabolism. BUN is measured in milligrams per deciliter (mg/dL) using an enzymatic assay in a certified laboratory, offering an indicator of renal health and nitrogen balance.

Secondary outcomes

  1. Center for Epidemiologic Studies Depression Scale (CES-D)

    Time frame: Up to 8 weeks.

    Assessment of depressive symptoms using the Center for Epidemiologic Studies Depression Scale (CES-D), a validated 20-item self-report questionnaire that measures the frequency of depressive symptoms experienced in the past week. Each item is scored on a 4-point Likert scale, ranging from 0 (rarely or none of the time) to 3 (most or all of the time), with a total score range of 0-60. Higher scores indicate more severe depressive symptoms.

  2. uroQol 5-Dimension 5-Level (EQ-5D-5L)

    Time frame: Up to 8 weeks.

    Assessment of health-related quality of life using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. This tool measures five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels, ranging from no problems to extreme problems, resulting in a single health state index score. Additionally, participants provide a self-rated health score on a visual analog scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better health-related quality of life.

  3. Multidimensional Sports Self-efficacy Scale (MSES)

    Time frame: Up to 8 weeks.

    Assessment of sports-related self-efficacy using the Multidimensional Sports Self-efficacy Scale (MSES), a validated questionnaire measuring an individual's confidence in performing various aspects of sports performance. The MSES includes subscales for different dimensions, such as physical skill, self-regulation, and coping with pressure. Each item is rated on a Likert scale from 1 (not at all confident) to 7 (extremely confident), with higher scores indicating greater self-efficacy in sports-related skills and resilience.

  4. Chinese self-efficacy for exercise scale (SEE-C)

    Time frame: Up to 8 weeks.

    Assessment of self-efficacy for exercise using the Chinese Self-Efficacy for Exercise Scale (SEE-C), a validated questionnaire designed to measure an individual's confidence in their ability to engage in and sustain exercise. The SEE-C consists of several items that assess self-efficacy across various domains such as initiation, maintenance, and overcoming barriers to exercise. Each item is rated on a Likert scale from 1 (not at all confident) to 5 (extremely confident), with higher scores reflecting greater confidence in one's ability to engage in regular physical activity.

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

Registry information

Official study title

the Real-world Data of Risk Factor and Its Prognosis in PREmature Coronary ARtery DIseAse Study (PRE-CARDIA)

Acronym: PRE-CARDIA

Important dates

Study start
2013
Primary completion
2024
Study completion
2027
First posted
Nov 19, 2024
Registry last updated
Nov 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.